You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Cryptogenic Stroke and Patent Foramen Ovale

Jaigobin, Cheryl MD

CONTINUUM: Lifelong Learning in Neurology:
doi: 10.1212/01.CON.0000410039.72594.03
Practice Issues

ABSTRACT: In patients with cryptogenic stroke and patent foramen ovale, options for stroke prevention include medical therapy (antiplatelet therapy or anticoagulation) and percutaneous device closure. In the only completed randomized controlled trial comparing medical therapy and percutaneous device closure, there was no difference in outcome between the two forms of treatment, and both are viable options for stroke prevention. The choice of therapy is made after careful weighing of potential risks and benefits associated with each form of therapy based on the limited evidence to date and the anticipated patient adherence with the planned treatment. Participation in a clinical trial is a third option for these patients.

Author Information

Address correspondence to Dr Cheryl Jaigobin, Toronto General Hospital, 5 Eaton Centre-Room 306, 200 Elizabeth Street, Toronto, ON M5G 2C4, Canada,

Relationship Disclosure: Dr Jaigobin reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Jaigobin reports no disclosure.

© 2011 American Academy of Neurology